|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2002-7-24
|
|
pubmed:abstractText |
To evaluate the efficacy and safety of pioglitazone hydrochloride 30 mg/day with sulphonylureas and metfomin in the treatment of patients with type 2 diabetes mellitus.
|
|
pubmed:language |
chi
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0578-1426
|
|
pubmed:author |
pubmed-author:DamW AWA,
pubmed-author:JiaPeihongP,
pubmed-author:LiGuangweiG,
pubmed-author:LinHuandongH,
pubmed-author:LuoBangyaoB,
pubmed-author:PanChangyuC,
pubmed-author:ShiHongliH,
pubmed-author:TianHuiH,
pubmed-author:XingXiaoyanX,
pubmed-author:YenI HIH,
pubmed-author:ZhaoYongjuY,
pubmed-author:ZhouLinuoL
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
41
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
388-92
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:12137601-Blood Pressure,
pubmed-meshheading:12137601-Body Weight,
pubmed-meshheading:12137601-Cholesterol,
pubmed-meshheading:12137601-Consumer Product Safety,
pubmed-meshheading:12137601-Diabetes Mellitus, Type 2,
pubmed-meshheading:12137601-Dose-Response Relationship, Drug,
pubmed-meshheading:12137601-Double-Blind Method,
pubmed-meshheading:12137601-Drug Therapy, Combination,
pubmed-meshheading:12137601-Female,
pubmed-meshheading:12137601-Heart Rate,
pubmed-meshheading:12137601-Humans,
pubmed-meshheading:12137601-Hypoglycemic Agents,
pubmed-meshheading:12137601-Insulin,
pubmed-meshheading:12137601-Male,
pubmed-meshheading:12137601-Metformin,
pubmed-meshheading:12137601-Sulfonylurea Compounds,
pubmed-meshheading:12137601-Thiazoles,
pubmed-meshheading:12137601-Thiazolidinediones,
pubmed-meshheading:12137601-Time Factors,
pubmed-meshheading:12137601-Treatment Outcome,
pubmed-meshheading:12137601-Triglycerides
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
[The efficacy and safety of pioglitazone hydrochloride in combination with sulphonylureas and metfomin in the treatment of type 2 diabetes mellitus a 12-week randomized multi-centres placebo-controlled parallel study].
|
|
pubmed:affiliation |
Department of Endocrinology, General Hospital of PLA, Beijing 100853, China.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
English Abstract,
Randomized Controlled Trial,
Multicenter Study
|
